New treatment approaches for lung cancer and impact on survival

2002 ◽  
Vol 29 (3 Suppl 8) ◽  
pp. 26-29 ◽  
Author(s):  
Hern[aacute]n Cort[eacute]s-Funes
Keyword(s):  
Lung Cancer ◽  
Treatment Approaches ◽  
Impact On Survival ◽  
New Treatment

Interstitial laser photocoagulation in canine lung: A preliminary investigation of a new treatment for lung cancer

1995 ◽  
Vol 2 (12) ◽  
pp. 1144
Author(s):  
Brian W. Goodacre ◽  
N.J. Finn ◽  
C.P. Nolsoe ◽  
O. Esch ◽  
G.R. Wittich ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Laser Photocoagulation ◽  
Preliminary Investigation ◽  
Interstitial Laser Photocoagulation ◽  
Interstitial Laser ◽  
New Treatment

Current status and new treatment approaches in TP53 mutated AML

2019 ◽  
Vol 32 (2) ◽  
pp. 134-144 ◽  
Author(s):  
Anthony M. Hunter ◽  
David A. Sallman
Keyword(s):  
Current Status ◽  
Treatment Approaches ◽  
New Treatment

A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care

2020 ◽  
Vol 26 (6) ◽  
pp. 1452-1460
Author(s):  
Osama M Al-Quteimat ◽  
Amer M Amer
Keyword(s):  
Lung Cancer ◽  
Patient Care ◽  
Treatment Option ◽  
Nsclc Patient ◽  
Active Member ◽  
Cost Effective Treatment ◽  
Platinum Based Chemotherapy ◽  
New Treatment ◽  
Egfr Mutant ◽  
Egfr Tkis

Lung cancer is a complex, genetically heterogeneous disease. It is the most common cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) represents the majority of the diagnosed lung cancer cases. Osimertinib is a new treatment option that demonstrated a superior efficacy over standard epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) or platinum-based chemotherapy. The safety and efficacy of osimertinib (a third generation EGFR-TKIs) were confirmed by well-designed clinical trials. Consequently, osimertinib was considered a first-line treatment option, particularly in patients with EGFR mutant NSCLC. It has been approved by FDA for the treatment of advance or metastatic NSCLC patients with specific EGFR-mutant NSCLC. As an active member of the multidisciplinary team, pharmacist has a promising role in assuring safe, effective and cost-effective treatment in patient with NSCLC. This review article aims to highlight the latest evidence about osimertinib use as a new treatment option in the clinical practice and to review the potential pharmacist key roles in NSCLC patient care.

Sign in / Sign up

Export Citation Format

Share Document